US 11,850,260 B2
Medicinal nanocomposite and method of preparation thereof
B. Rabindran Jermy, Dammam (SA); Vijaya Ravinayagam, Dammam (SA); and Suriya Rehman, Dammam (SA)
Assigned to Imam Abdulrahman Bin Faisal University, Dammam (SA)
Filed by Imam Abdulrahman Bin Faisal University, Dammam (SA)
Filed on Feb. 4, 2022, as Appl. No. 17/665,014.
Prior Publication US 2023/0248765 A1, Aug. 10, 2023
Int. Cl. A61K 33/38 (2006.01); A61K 47/02 (2006.01); A61P 31/04 (2006.01); A61K 33/243 (2019.01)
CPC A61K 33/38 (2013.01) [A61K 33/243 (2019.01); A61K 47/02 (2013.01); A61P 31/04 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A medicinal nanocomposite, comprising:
80 to 99 wt. % carrier particles of a porous silicate material selected from the group consisting of mesoporous silica, silicalite, mesosilicalite, silver-incorporated silicalite, and silver-incorporated mesosilicalite, the carrier particles comprising a pore framework;
0.5 to 10 wt. % silver nanoparticles (Ag NPs) dispersed on the pore framework, the silver nanoparticles being distinct from silver present in the silver-incorporated silicalite and/or silver-incorporated mesosilicalite; and
0.5 to 10 wt. % of a platinum-containing pharmaceutical compound disposed on at least one surface selected from an interior pore surface of the carrier particles, an exterior surface of the carrier particles, and a surface of the silver nanoparticles,
wherein the medicinal nanocomposite releases less than 10 mol. % of the platinum-containing pharmaceutical compound after 60 to 84 hours at a pH of 4.5, based on an initial amount of the platinum-containing pharmaceutical compound present in the medicinal nanocomposite.